retapamulin | 1452791-70-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: retapamulin
• 英文别名: (3aS,4R,5S,6S,8R,9R,9aR,10R)-2-(exo-8-Methyl-8-azabicyclo[3.2.1]octan-3-ylsulfanyl)acetic acid 5-hydroxy-4,6,9,10-tetraMethyl-1-oxo-6-vinylperhydro-3a,9-propanocyclopentacycloocten-8-yl ester (RETAPAM；[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)sulfanyl]acetate
• CAS: 1452791-70-6
• 化学式: C₃₀H₄₇NO₄S
• 分子量: 517.773
• InChiKey: STZYTFJPGGDRJD-OSBNDYPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  92.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyl-5-hydroxy-4,6,9,10-tetramethyl-1-oxodecahydro-3a,9-propanocyclopenta[8]annulen-8-yl{[(1R,3s,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]sulfanyl}acetate fumarate 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 retapamulin
  参考文献：
  名称：

  WO2009/95634

  摘要：

  公开号：

文献信息

• 12-EPI PLEUROMUTILINS
  申请人：NABRIVA THERAPEUTICS AG

  公开号：US20160332963A1

  公开（公告）日：2016-11-17

  A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

  从14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-硫基)-乙酰基]-12-epi-木替林，或14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-氧基)-乙酰基]-12-epi-木替林中选择的一种化合物，其中12-epi-木替林的特征在于木替林环在位置12被两个取代基取代，木替林环在位置12的第一个取代基是一个甲基基团，该甲基基团的立体化学与天然存在的普鲁木替林环在位置12的甲基基团的立体化学相反，木替林环在位置12的第二个取代基是一个含有至少一个氮原子的碳氢基团，木替林环的所有其他取代基与天然存在的普鲁木替林环中相应位置的取代基的立体化学相同；可选地以盐和/或溶剂的形式存在，其中天然存在的普鲁木替林的化学式为 制备这类化合物的方法以及它们作为药物的用途。
• NOVEL PROCESS, SALTS, COMPOSITION AND USE
  申请人：Breen Gary Francis

  公开号：US20110144151A1

  公开（公告）日：2011-06-16

  The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.

  本发明提供了一种制备噻唑菌素衍生物的新工艺，以及新的噻唑霉素14-(外消旋-8-甲基-8-氮杂双环[3.2.1]辛-3-基硫酰基)乙酸盐或其溶剂化物，新的药物组合物或制剂，用于局部给药，包括噻唑霉素14-(外消旋-8-甲基-8-氮杂双环[3.2.1]辛-3-基硫酰基)乙酸盐或其药学上可接受的盐或溶剂化物，并用于医疗治疗，特别是抗菌治疗。
• Process for the preparation of Retapamulin and its intermediates
  申请人：Hedvati Lilach

  公开号：US20090149655A1

  公开（公告）日：2009-06-11

  Processes for preparing tropine derivatives of the following Formula B are provided where LG represents a leaving group. The tropine derivatives may be used to prepare Retapamulin, preferably in substantially pure form. Also provided are processes for preparing Retapamulin comprising combining a base, tropine thiol in a free base or salt form, an organic solvent, and a pleuromutilin derivative of Formula A:

  提供了制备以下公式中LG代表离去基的托品衍生物的过程。这些托品衍生物可用于制备Retapamulin，最好是在基本纯净的形式。还提供了制备Retapamulin的过程，包括结合一种碱、托品硫醇（以自由碱或盐的形式）、有机溶剂和公式A的多肽杀菌素衍生物。
• Small molecules active against gram-negative bacteria
  申请人：The Board of Trustees of the University of Illinois

  公开号：US10995097B2

  公开（公告）日：2021-05-04

  Disclosed are compounds that accumulate in Gram-negative bacteria. Also disclosed are method of antimicrobial treatment using the compounds.

  公开了可在革兰氏阴性细菌中蓄积的化合物。还公开了使用这些化合物进行抗菌治疗的方法。
• 12-EPI-PLEUROMUTILINS
  申请人：Nabriva Therapeutics GmbH

  公开号：EP3096751B1

  公开（公告）日：2021-01-06